Letter from LRA President & CEO Albert T. Roy
Dear Friends,
Lupus Awareness Month begins today, and with it comes a renewed sense of purpose, momentum, and possibility. Thanks...
Stories & News
Saphnelo™ Approved as Self-Administered Autoinjector
The U.S. Food and Drug Administration just granted approval for a self-administered, once-weekly autoinjector of Saphenlo (anifrolumab), for the treatment of adult patients...
Debbie Schwartz: Advocating in Every Sense of the Word
Debbie Schwartz is absolutely convinced that a cure for lupus will be found in her lifetime.
Why? Because she’s done something like this once before.
Debbie previously dealt with epileptic...
New Findings from Lupus Research Alliance-Funded Researcher Links Common Gut Bacteria to Lupus Flares
LRA-funded researcher Gregg Silverman, MD, NYU Grossman School of Medicine, is the lead author on a new study published...
FDA Accepts Application for Gazyva® (obinutuzumab) to Treat SLE
The U.S. Food and Drug Administration has accepted the supplemental Biologics License Application from Genentech for Gazyva® (obinutuzumab) to treat systemic lupus erythematosus (SLE), the most common form of...
New Phase 2 Data Showed that Litifilimab Significantly Reduced Disease Activity in Cutaneous Lupus Erythematosus
The Lupus Research Alliance welcomes new results from the Phase 2 part of the AMETHYST Phase 2/3 study, showing that the...
Submit a Lupus Awareness Month Proclamation in Your Community
May is recognized worldwide as Lupus Awareness Month, a time when attention is focused on lupus, a serious, often overlooked, and frequently misdiagnosed autoimmune disease with...
LRA Progress & Purpose Update | Albert T. Roy – March 2026
Hear from President and CEO Albert T. Roy as he recaps the organization’s exciting achievements from the first months...
Faith Majors: Living with Lupus and Refusing to Give Up
The stats are all too familiar – nine out of ten people with lupus are women. During Women’s History...
New Phase 3 Study Shows that Gazyva® (obinutuzumab) Significantly Reduces Lupus Disease Activity in SLE
A new Phase 3 study published in the New England Journal of Medicine found that Gazyva® (obinutuzumab) significantly reduced disease...
Run 2026 TCS New York City Marathon for Lupus Research
Be Part of Team Life Without Lupus® in the TCS New York City Marathon! AND MAKE HISTORY
On Sunday, November...
Clinical Affiliate Lupus Therapeutics Expands Peer-to-Peer Program
New Centralized Model to Include Hundreds of Research Sites Across North America The clinical affiliate of the Lupus Research Alliance,...